Lidegaard 2012a.

Methods	Cohort study
Participants	5036 events/9,336,662 person years Aged 15 to 49 years
Interventions	Combined oral contraception: current use, none use, 1st generation, 2nd generation, 3rd generation, 20 µg oestrogen, 30 to 49 µg oestrogen, ≥ 50 µg oestrogen, levonorgestrel, norethindrone, norgestimate, desogestrel, gestodene, drospirenone, cyproterone acetate
Outcomes	Myocardial infarction and ischemic stroke Events: current use 1548/4,528,151, none use 3488/9,336,662, 1st generation 62/170,218, 2nd generation 303/515,033, 3rd generation 920/3,345,929, levonorgestrel 303/515,033, norethindrone 62/170,218, norgestimate 106/453,536, desogestrel 287/1,009,163, gestodene 527/1,883,230, drospirenone 70/286,770, cyproterone acetate 41/187,145.
Notes	Denmark
Risk of bias
Bias	Authors' judgement	Support for judgement
Exposure ascertainment	Low risk	COC use objectively confirmed.
Outcome assessment	High risk	Information on myocardial infarction and ischemic stroke obtained from a diagnostic registry
Follow‐up	Low risk	No loss to follow up.
Source population	Unclear risk	Not applicable as this was a population study.